已发表论文

SUVmax 和代谢肿瘤体积:结直肠癌中 KRAS 突变状态的替代图像生物标志物

 

Authors Lv Y, Wang X, Liang L, Wang L, Lu J

Received 1 December 2018

Accepted for publication 5 February 2019

Published 21 March 2019 Volume 2019:12 Pages 2115—2121

DOI https://doi.org/10.2147/OTT.S196725

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr William Cho

Purpose: The objective of this study was to explore the association between KRAS mutation status and PET/CT metabolic parameters in colorectal cancer (CRC) patients.
Materials and methods: One hundred and sixty-four CRC patients were enrolled in this study and received PET/CT examination before operation, then KRAS mutation status was analyzed through pathologically confirmed CRC samples. The association between tumor clinical characteristics and PET/CT metabolic parameters, including maximum standardized uptake value (SUVmax), SUVmean, and metabolic tumor volume (MTV), and KRAS mutation status was analyzed using chi-squared tests, Mann–Whitney  tests, and logistic regression analysis.
Results: The KRAS mutation type patients exhibited high MTV and high SUVmax using a threshold of 17.8 cm3 and 8.7 respectively and the predictive accuracy was 0.772 and 0.603 respectively. High MTV (=0.001; 95% CI: 1.119–1.296) and high SUVmax (=0.048; 95% CI: 0.564–0.985) were independent predictors for KRAS mutation status.
Conclusion: MTV and SUVmax were associated with KRAS mutation type in CRC patients. PET/CT metabolic parameters can be used for supplementing KRAS mutation status prediction in CRC patients.
Keywords: colorectal cancer, 18F-FDG PET/CT, SUVmax, SUVmean, MTV, KRAS mutation




Figure 1 Analysis of SUVmax and MTV according to KRAS mutation status.